3 Bethesda Metro Center, #700
About Cannabics PharmaceuticalsCannabics Pharmaceuticals is dedicated to the development of Personalized Anti-Cancer treatments.
Founder and CEO: Itamar Borochov
Tweets by Cannabics
99 articles with Cannabics Pharmaceuticals
In the news release, Cannabics Pharmaceuticals Announces New Provisional Patent Application for Magnetic Targeting of Cannabinoids, issued Nov. 28, 2018 by Cannabics Pharmaceuticals Inc. over PR Newswire, we are advised by the company that the original release was issued inadvertently with imprecise information.
CEO of Cannabics Pharmaceuticals Presenting at 11th Annual LD Micro Conference, on December 5th, 2018 in LA, California
Cannabics Pharmaceuticals Inc. today announced that Mr. Eyal Barad, CEO, will be presenting at the LD Micro Main Event.
Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, today announced their CEO, Eyal Barad, will speak on a panel at the Marijuana Business Conference
Cannabics Pharmaceuticals Granted Patent in South Africa for Its Personalized Cannabinoid Based Diagnostics
Cannabics Pharmaceuticals Inc. announced today that it has been granted its patent for its core technology by the South Africa Patent Office.
Cannabics Pharmaceuticals Announces Positive Results for Pilot Study on Treatment of Cancer Anorexia-Cachexia Syndrome (CACS)
Preliminary findings showed more than 80 percent of patients had increase in appetite and 60 percent of patients had over 10 percent weight increase
Join Cannabics Pharmaceuticals at the 3rd CannX Medical Cannabis Conference, Held at Tel-Aviv Convention Center, Israel, October 14-16, 2018
Cannabics Pharmaceuticals Inc. announced today that members of its management team will be attending the 3rd CannX Medical Cannabis Conference, to be held in the Tel Aviv Convention Centre, on October 14th – 16th 2018, and will be available for one-on-one meetings.
Eroll Grow Tech (Seedo) Merges Its Activities With GRCR Partners; Cannabics Pharmaceuticals to Own 13.6% in the Merged Company
GRCR is traded on the OTC stock Exchange
Cannabics Pharmaceuticals Receives Positive Results in the Development of Cannabinoid-anticancer Drugs
Cannabics Pharmaceuticals (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, today announced it has received encouraging results in its preclinical study showing one of its proprietary cannabinoid compounds causing higher rate of cancer cell death compared to traditional chemotherapy (fig.1).
Cannabics Pharmaceuticals Granted Patent in Israel for Its Core Technology for Personalized Cannabinoid Based Medicine
Cannabics Pharmaceuticals Inc. has been granted its patent for its core technology by the Israeli Patent Office.
Cannabics Pharmaceuticals Announces That Seedo is to End Pre-Sales and Commence Delivery of Its Automated Growing Devices
Seedo will end pre-sales on September 12th and commence delivery in the next coming weeks
Cannabics Pharmaceuticals Partners with Eroll Grow Tech to Create First Auto-Grow Device for Medical Cannabis
Companies will develop controlled propagation facilities for the medical cannabis industry
Cannabics Pharmaceuticals Inc. announced today that its CEO, Mr. Eyal Barad, will be attending the Benzinga Cannabis Capital Conference, to be held at the Toronto Arcadian Centre, on August 16th-17th 2018, and will be available for one on one meetings.
"Exploring complementary Disruptive Technologies to add to our core Science"
Join Cannabics Pharmaceuticals at the National Cannabis Industry Association's Cannabis Business Summit and Expo Held at San Jose Convention Center, California USA, July 25-27, 2018
Cannabics Pharmaceuticals Inc. announced that senior members of its team will be attending the National Cannabis Industry Association Business Conference and Expo, to be held in San Jose convention center, California, USA, on July 25th-27th 2018, and will be available for one on one meetings.
Cannabics Pharmaceuticals Announces Conclusion of Clinical Trial on Cannabics SR 5mg for Cancer Anorexia Cachexia Syndrome (CACS)
Cannabics Pharmaceuticals Inc. announced that it has concluded its clinical trial held at Rambam Medical Center.
Cannabics Pharmaceuticals Enters a Memorandum of Understanding With Clinical-Stage Biopharmaceutical Company Focused on the Treatment of Ophthalmic Disorders
Cannabics Pharmaceuticals Inc. announced that it has entered a memorandum of understanding with a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders.
Cannabics Pharmaceuticals Announces Collaboration With Life Source Partners CEO Muriel Zohar to Optimize Technology Applications and Evaluate New Opportunities
Dr. Zohar will support strategic business planning as Cannabics enters $10 million Standby Equity Distribution Agreement with YAII PN, Ltd.
Cannabics patent granted with enabling technology to personalize Cannabinoid diagnostics and treatment for Cancer patients
Cannabics Pharmaceuticals Hires Chief Data Officer to Address Industry Compliance and Utilization/Analytics Application
Cannabics Pharmaceuticals announced the appointment of Yasha Borstein as the company's Chief Data Officer.
Cannabics Pharma Files an International Patent Application on Methods for Testing and Predicting Therapeutic Effectiveness of Cannabinoids for Cancer Patients
Cannabics Pharmaceuticals announced today that it has filed an international patent application with the PCT authorities on methods for testing which cannabinoids or combinations of cannabinoids are likely be effective in individual patients.